- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, December 22, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A study titled “Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes,” published in the December 2023 issue of The American Journal of Managed Care® (AJMC®), was referenced in articles from Physician’s Weekly, DocWire News, and HCPLive. The study found that approximately 40% of patients with type 2 diabetes discontinued their second-line therapies within a year.
An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Top 5 Conference Coverage of 2023,” collected the most-viewed items on AJMC.com that reported on new research presented at medical conferences that AJMC editors attended throughout the year, including the Annual Meeting of the American Society of Clinical Oncology and the European Hematology Association Congress.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
